Eiger will also host one-on-one meetings with investors at the SunTrust Robinson Humphrey 2017 Orphan Drug Day conference on Tuesday, February 14, 2017, at the JW Marriott Essex House in New York City.
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors: Andrew McDonald, LifeSci Advisors, LLC, 646-597-6987
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-bio-ceo--investor-conference-february-13th-and-participate-in-suntrust-robinson-humphrey-orphan-drug-day-conference-february-14th-300398543.html
SOURCE Eiger BioPharmaceuticals, Inc.